Welcome to our dedicated page for Belite Bio SEC filings (Ticker: BLTE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Belite Bio, Inc (NASDAQ: BLTE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer, including Form 6‑K current reports and shelf registration materials. These documents show how Belite Bio communicates key developments around its clinical programs, financings, and regulatory interactions for its lead candidate, Tinlarebant.
Belite Bio uses Form 6‑K to furnish press releases on topics such as quarterly financial results and corporate updates, completion of enrollment in pivotal trials like the global Phase 3 PHOENIX study in geographic atrophy, and progress in the Phase 3 DRAGON program in Stargardt disease type 1 (STGD1). Other 6‑K filings describe securities purchase agreements for registered direct offerings and private placements, including details on American Depositary Shares, warrants, and registration rights agreements.
Through its filings, the company also references its shelf registration statement on Form F‑3, which supports offerings of American Depositary Shares used to fund clinical development, regulatory milestones, and commercialization preparation. While Belite Bio’s filings do not include U.S. domestic forms such as 10‑K or 10‑Q, they serve a similar role in updating investors on business progress, clinical trial status, and capital structure.
On Stock Titan, users can review Belite Bio’s SEC submissions in one place and use AI-powered summaries to interpret complex financing terms, understand the context of clinical and regulatory announcements, and see how new capital raises relate to ongoing trials in STGD1 and geographic atrophy. Filings related to equity offerings, warrants, and registration rights can help readers follow potential dilution, capital availability, and the company’s strategy for funding late-stage drug development.
Belite Bio Chief Scientific Officer Nathan L. Mata reported open-market sales of company stock. On May 1, 2026, he sold a total of 1,000 American depositary shares (ADS), with each ADS representing one ordinary share of Belite Bio.
The sales were executed in multiple trades at prices ranging from about $153.8 to $160 per ADS and were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. The filing does not show any option exercises or derivative transactions alongside these sales.
Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of the company in open-market transactions. The sales occurred on April 30, 2026 at weighted average prices reported between $155.62 and $158.42 per share.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. Following the sales, Mata directly holds 4,666 American depositary shares of Belite Bio, Inc.
Belite Bio Chief Scientific Officer Nathan L. Mata sold a total of 1,000 American depositary shares in open-market transactions on April 29, 2026. The sales occurred at weighted average prices ranging from about $154.22 to $158.21, according to the filing footnotes.
The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. After these sales, Mata directly holds 5,666 ADS of Belite Bio.
Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares (ADS) of BELITE BIO, INC in open-market transactions on April 28, 2026. The ADS were sold in multiple small trades at weighted average prices ranging from $154.62 to $162.59 per ADS.
The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the executive on December 10, 2025, indicating they were scheduled in advance. Following these transactions, he directly owned 7,654 ADS of the company.
Belite Bio Chief Scientific Officer Nathan L. Mata reported selling a total of 1,000 American depositary shares in open-market transactions. The sales occurred on April 27, 2026 at prices ranging from about $160.83 to $164.07 per share. Following these trades, he directly holds 7,666 American depositary shares, each representing one ordinary share of Belite Bio. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on 12/10/2025, indicating the sales were scheduled in advance rather than timed discretionarily.
Belite Bio chief scientific officer Nathan L. Mata reported open‑market sales of 1,000 American depositary shares (ADS) of the company. The transactions occurred on April 24 and were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 10, 2025.
The ADS were sold in multiple trades at prices including $162.53 and various weighted average prices in the high‑$150s to low‑$160s. Following these sales, Mata directly owns 8,666 ADS, each representing one ordinary share of Belite Bio.
Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of the company on April 23, 2026. The sales were open-market transactions at prices ranging from about $164 to $170 per ADS and were executed under a Rule 10b5-1 trading plan adopted on 12/10/2025.
BELITE BIO, INC director and CEO Yu-Hsin Lin reported a compensation-related share vesting. On 04/21/2026, 10,000 ordinary shares were delivered upon vesting of restricted stock units granted on September 15, 2025 after specified performance criteria were met.
Following this non-market transaction, Lin directly holds 182,949 ordinary shares. The event reflects equity-based compensation vesting rather than an open-market purchase or sale.
Belite Bio’s Chief Medical Officer, Hendrik Peter Scholl, reported the vesting of a performance-based stock option held indirectly through Bioptima Ltd. The option covers 10,000 ordinary shares at an exercise price of $77.40 per share.
The option was originally granted on October 7, 2025 and vested on April 21, 2026 after specified performance criteria were met. Following this vesting event, 10,000 stock option rights remain outstanding under this grant, with an expiration date of October 6, 2035. This filing reflects a compensation-related milestone rather than an open-market share purchase or sale.
Belite Bio chief scientific officer Nathan L. Mata sold 1,000 American depositary shares of the company in open-market transactions. The Form 4 shows nine sales of Belite Bio ADS on April 22, 2026, at weighted average prices ranging from about $165.64 to $173.16. The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. Each ADS represents one ordinary share of Belite Bio.